Effects of Pleuran (Β–Glucan from Pleurotus Ostreatus) Supplementation on Incidence and Duration of COPD Exacerbations
DOI:
https://doi.org/10.3889/oamjms.2017.198Keywords:
Chronic obstructive pulmonary disease, Exacerbations, Beta glucans, Pleuran, SupplementAbstract
BACKGROUND: 1,3/1,6-β–glucans are recognised as immunomodulators in human and veterinary medicine for over 50 years.
AIM: To assess the effects of pleuran (1,3/1,6-β–glucan from Pleurotus ostreatus) on incidence and duration of bacterial exacerbations in patients with COPD.
METHODS: We performed an observational, non-randomized, open-label study including 32 COPD patients (Group D) in whom besides the recommended chronic treatment for the stable disease were administered supplement combination containing pleuran 100 mg, vitamin C 60 mg and zinc 5 mg once daily over a three month-period (Group 1). Also, an equal number of Group D COPD patients who besides the recommended treatment for stable disease received the supplement combination containing vitamin C 60 mg and zinc 5 mg once daily, matched to the study subjects of the Group 1 by sex and age served as control (Group 2).
RESULTS: Over the study period 57 exacerbations (24 in the Group 1 and 33 in the Group 2) were documented. A mean number of exacerbations over the study period was significantly lower in the Group1 (0.7 ± 0.4) as compared to their mean number in the Group 2 (1.0 ± 0.6) (P = 0.0218). Furthermore, a mean duration of exacerbations expressed in days needed for cure or clinical improvement (i.e. complete resolution of symptoms or return of the symptoms to their baseline severity) in the Group 1 (6.7 ± 0.8 days) was significantly shorter than the mean duration of exacerbations in the Group 2 (7.4 ± 1.3 days) (P = 0.0118). There was not reported any adverse effect during the study period by study subjects from both examined groups.
CONCLUSION: Our findings indicated that pleuran might impact the incidence and duration of bacterial exacerbations in patients with COPD. There is a need for further studies for more precise determination of the influence of pleuran on the course of COPD.Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PloS Med. 2006; 3: e442. https://doi.org/10.1371/journal.pmed.0030442 PMid:17132052 PMCid:PMC1664601
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2014 Update. Available at: http://www.goldcopd.org/ (Accessed 14.04.2017).
Global Initiative for Chronic Obstructive Pulmonary Disease. A pocket guide to COPD diagnosis, management and prevention: Updated 2015. Available at: http://www.goldcopd.org/ (Accessed 14.04.2017).
Bohn JA, BeMiller JN. (1-3)-beta-D-glucans as biological response modifiers: a review of structure-function relationships. Carbohydr Polymers. 1995; 28: 3-14. https://doi.org/10.1016/0144-8617(95)00076-3
Raa J. Immune modulation by non-digestible and non-apsorbable beta-1,3/1,6-glucan. Microbial Ecology in Health & Disease. 2015; 26: 27824. https://doi.org/10.3402/mehd.v26.27824 PMid:26031679 PMCid:PMC4451094
Vannucci L, Krizan J, Sima P, et al. Immunomodulatory properties and antitumor activities of glucans (Review). International Journal of Oncology. 2013; 43: 357-364. https://doi.org/10.3892/ijo.2013.1974 PMid:23739801 PMCid:PMC3775562
Yap AT, Ng ML. An important method for the isolation of lentina from edible and medicinal shitake mushroom, Lentinus edodes (Berk.) Sing. (Agaricomycetideae). In J Med Mushr. 2001; 3: 6-19.
Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature. 2001; 413: 36-37. https://doi.org/10.1038/35092620 PMid:11544516
Goodridge HS, Wolf AJ, Underhill DM. Beta-glucan recognition by the innate immune system. Immunol Rev. 2009; 230 (1): 38-50. https://doi.org/10.1111/j.1600-065X.2009.00793.x PMid:19594628
Batbayar S, Lee DH, Kim HW. Immunomodulation of fungal ï¢-glucan in host defense signaling by dectin-1. Biomol Ther. 2012; 20 (5): 433-445. https://doi.org/10.4062/biomolther.2012.20.5.433 PMid:24009832 PMCid:PMC3762275
Volman JJ, Ramakers JD, Plat J. Dietary modulation of immune function by beta-glucans. Physiol Behav. 2008; 94: 276-284. https://doi.org/10.1016/j.physbeh.2007.11.045 PMid:18222501
Spirometry Guide: 2010 Update. Available at: http://www.goldcopd.org/uploads/users/files/GOLD_Spirometry_2010. (Accessed: 16.04.2017).
Calculate your Body Mass Index. Available at: https://www.nhlbi.nih.gov (Accessed: 16.04.2017).
World Health Organization. Guidelines for controlling and monitoring the tobbaco epidemic. Geneva: WHO, 1998.
U.S. Department of Health and Human Services. The health consequences of smoking: chronic obstructive pulmonary disease. A report of the Surgeon General. US Department of Health and Human Services, Public Health Service, Office of the Assistant for Health, Office of Smoking and Health. DHHS Publication No. 84-50 205, 1984.
Janson C, Chinn S, Jarvis D, et al. Effects of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study. Lancet. 2001; 358: 2103-2109. https://doi.org/10.1016/S0140-6736(01)07214-2
Anthonisen NR, Menfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987; 106 (2): 196-204. https://doi.org/10.7326/0003-4819-106-2-196 PMid:3492164
Minov J, Karadzinska-Bislimovska J, Nelovska Z, Vasilevska K, Risteska-Kuc S, Stoleski S, Mijakoski D. Smoking among Macedonian workers five years after anti-smoking campaign. Arh Hig Rada Toksikol. 2012; 63: 207-213. https://doi.org/10.2478/10004-1254-63-2012-2150 PMid:22728803
Minov J. Smoking among Macedonian Workers. Saarbrücken: LAP LAMBERT Academic Publishing, 2013.
Cassone A, Bistoni F, Cenci E, et al. Immunopotentiation of anticancer therapy by Candida albicans, other yeasts and insoluble glucan in an experimental lymphoma model. Sabouraudia. 1982; 20: 115-125. https://doi.org/10.1080/00362178285380191 PMid:7051368
Zhang Y, Xia L, Pang W, et al. A novel soluble β-1,3-d-glucan Salecan reduces adiposity and improve glucose tolerance in high-fat diet-fed mice. Br J Nutr. 2012; 13: 1-9.
Haggard L, Andersson M, Punga AR. ï¢-glucans reduce LDL cholesterol in patients with myastenia gravis. Eur J Clin Nutr. 2013; 67: 226-227. https://doi.org/10.1038/ejcn.2012.191 PMid:23187951
Jesenak M, Majtan J, Rennerova Z, et al. Immunomodulatory effect of pleuran (ï¢-glucan from Pleurotus ostreatus) in children with recurrent respiratory tract infections. Int Immunopharmacol. 2013; 15 (2): 395-399. https://doi.org/10.1016/j.intimp.2012.11.020 PMid:23261366
Pico Sirvent L, Sapena Grau J, Morera Ingles M, Rivero Urgell M. Effect of supplementation with β–glucan from Pleurotus ostreatus in children with recurrent respiratory infections. Ann Nurr Metab. 2013; 63 (1): 1378.
Bergendiova K, Tibenska E, Majtan J. Pleuran (ï¢-glucan from Pleurotus ostreatus) supplementation, cellular immune response and respiratory tract infections in athletes. Eur J Appl Physiol. 2011; 111 (9): 2033-2040. https://doi.org/10.1007/s00421-011-1837-z PMid:21249381
Bobovcak M, Kuniakova R, Gabriz J, Majtan J. Effect of Pleuran ((ï¢-glucan from Pleurotus ostreatus) supplementation on cellular immune response after intensive exercise in elite athletes. Appl Physiol Nutr Metab. 2010; 35 (6): 755-762. https://doi.org/10.1139/H10-070 PMid:21164546
Downloads
Published
How to Cite
Issue
Section
License
http://creativecommons.org/licenses/by-nc/4.0
